Cyrielle Caussy

List of Publications by Year
in descending order

43	3,478	279487	288905
papers	citations	23 h-index	40 g-index

45	45	45	5004
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metabolism, 2017, 25, 1054-1062.e5.	7.2	748
2	Noninvasive, Quantitative Assessment of Liver Fat by MRIâ€PDFF as an Endpoint in NASH Trials. Hepatology, 2018, 68, 763-772.	3.6	299
3	Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clinical Gastroenterology and Hepatology, 2019, 17, 630-637.e8.	2.4	254
4	Optimal threshold of controlled attenuation parameter with MRIâ€PDFF as the gold standard for the detection of hepatic steatosis. Hepatology, 2018, 67, 1348-1359.	3.6	250
5	A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nature Communications, 2019, 10, 1406.	5.8	218
6	Prevalence of obesity among adult inpatients with COVID-19 in France. Lancet Diabetes and Endocrinology,the, 2020, 8, 562-564.	5.5	194
7	A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell Metabolism, 2020, 32, 878-888.e6.	7.2	167
8	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. Journal of Clinical Investigation, 2017, 127, 2697-2704.	3.9	137
9	Obesity is Associated with Severe Forms of COVIDâ€19. Obesity, 2020, 28, 1175-1175.	1.5	130
10	Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut, 2020, 69, 1877-1884.	6.1	127
11	Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2018, 155, 307-310.e2.	0.6	113
12	EASLâ€“EASDâ€“EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?. Diabetologia, 2017, 60, 1218-1222.	2.9	95
13	Serum bile acid patterns are associated with the presence of NAFLD in twins, and doseâ€dependent changes with increase in fibrosis stage in patients with biopsyâ€proven NAFLD. Alimentary Pharmacology and Therapeutics, 2019, 49, 183-193.	1.9	80
14	The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Current Diabetes Reports, 2021, 21, 15.	1.7	78
15	Relationship between obesity and severe <scp>COVID</scp>â€19 outcomes in patients with type 2 diabetes: Results from the <scp>CORONADO</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 391-403.	2.2	69
16	An APOA5 3â€² UTR Variant Associated with Plasma Triglycerides Triggers APOA5 Downregulation by Creating a Functional miR-485-5p Binding Site. American Journal of Human Genetics, 2014, 94, 129-134.	2.6	58
17	Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. Gut, 2019, 68, 1884-1892.	6.1	48
18	Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 1974-1982.e7.	2.4	46

#	Article	IF	Citations
19	Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imagingâ€“Proton Density Fat Fraction as the Standard. Clinical Gastroenterology and Hepatology, 2020, 18, 1842-1850.e6.	2.4	37
20	An artificial neural network to predict resting energy expenditure in obesity. Clinical Nutrition, 2018, 37, 1661-1669.	2.3	32
21	PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. International Journal of Molecular Sciences, 2022, 23, 4305.	1.8	28
22	Glyphosate Excretion is Associated With Steatohepatitis and Advanced Liver Fibrosis in Patients With Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 741-743.	2.4	27
23	Liver Stiffness Severity is Associated With Increased Cardiovascular Risk in Patients With Type 2 Diabetes. Clinical Gastroenterology and Hepatology, 2020, 18, 744-746.e1.	2.4	26
24	BMI and pneumonia outcomes in critically ill COVIDâ€19 patients: An international multicenter study. Obesity, 2021, 29, 1477-1486.	1.5	24
25	Multiple microRNA regulation of lipoprotein lipase gene abolished by 3â€²UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter. Atherosclerosis, 2016, 246, 280-286.	0.4	23
26	Collagen Formation Assessed by Nâ€Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. Hepatology, 2019, 70, 127-141.	3.6	21
27	New rare genetic variants of LMF1 gene identified in severe hypertriglyceridemia. Journal of Clinical Lipidology, 2018, 12, 1244-1252.	0.6	19
28	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. Diabetes and Metabolism, 2021, 47, 101272.	1.4	18
29	Alterations in plasma triglycerides lipolysis in patients with history of multifactorial chylomicronemia. Atherosclerosis, 2017, 265, 22-28.	0.4	12
30	Magnetic resonanceâ€based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Endocrinology, Diabetes and Metabolism, 2020, 3, e00134.	1.0	11
31	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1253-1266.	1.4	9
32	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<scp>NAFLD</scp>). Alimentary Pharmacology and Therapeutics, 2022, 55, 1441-1451.	1.9	9
33	History of bariatric surgery and COVIDâ€19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. Obesity, 2022, 30, 599-605.	1.5	7
34	Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3â€²UTR variant SstI. Atherosclerosis, 2016, 255, 6-10.	0.4	6
35	Should We Screen High-Risk Populations for NAFLD?. Current Hepatology Reports, 2019, 18, 433-443.	0.4	6
36	Harmonic wideband simultaneous dualâ€frequency MR Elastography. NMR in Biomedicine, 2021, 34, e4442.	1.6	2

#	Article	IF	Citations
37	Short echo time dual-frequency MR Elastography with Optimal Control RF pulses. Scientific Reports, 2022, 12, 1406.	1.6	2
38	Editorial: screening for hepatocellular carcinoma in <scp>NAFLD</scp>â€"towards abbreviated <scp>MRI</scp> alternative in patients with obesity?. Alimentary Pharmacology and Therapeutics, 2022, 55, 1210-1211.	1.9	2
39	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 2140.	2.4	0
40	Non-alcoholic fatty liver disease and chronic kidney disease: renal benefit with liver stiffness assessment?. Diabetes and Metabolism, 2020, 46, 259-260.	1.4	0
41	La stÃ©atopathie dysmÃ©tabolique ou NASHÂ: faut-il dÃ©pister les patients Ã haut risque atteints de diabÃ¨te de type 2Âou dâ€™obÃ©sitÃ©Â?. Nutrition Clinique Et Metabolisme, 2020, 34, 122-129.	0.2	0
42	Undernourished patients do not have increased risk of severe COVID-19 outcomes. Clinical Nutrition Open Science, 2022, , .	0.5	0
43	Letter: nonâ€invasive prediction models to exclude cirrhosis in <scp>NAFLD</scp> â€"not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 182-183.	1.9	0